PUBLIC COMPANY
save$MLTXMoonLake Immunotherapeutics
$MLTX11.36-2.95%Zug, CHupdated 3h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
- phase3Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
- phase3Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- phase3Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
- phase3A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
- phase3An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
- phase1An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector
- phase3A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 14, 26SELLBodenstedt Matthias· Chief Financial Officer−$47K↗
- Apr 13, 26SELLSantos da Silva Jorge· Chief Executive Officer−$946K↗
- Apr 10, 26SELLSantos da Silva Jorge· Chief Executive Officer−$1.81M↗
- Apr 10, 26SELLBodenstedt Matthias· Chief Financial Officer−$38K↗
- Apr 9, 26SELLBodenstedt Matthias· Chief Financial Officer−$1.63M↗
🐶 Hiring Signal
News
- STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapiesGerman researcher Georg Schett has made a name for himself as a pioneer in autoimmune disease treatment. Now he's co-founding his own company.stat · 1mo ago
- STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts sayA newly approved drug for Prader-Willi syndrome, a rare disease that causes an insatiable desire to eat, may be tied to a series of patient deaths, experts say.stat · 1mo ago
- STAT+: Trump is counting on the health care industry to remake vaccines. It’s pushing back insteadTrump wants to change how American kids are vaccinated, but doctors and the pharma industry aren't on board.stat · 1mo ago
- STAT+: Skylark Bio kicks off new gene therapy trial for deafnessBiotech startups in the U.S., France, and China are racing to bring new gene therapies for deafness by targeting different genetic mutations.stat · 1mo ago
- STAT+: Nurses seek a seat at the table as they fight expanding clinical AINurses, who make up the largest part of the health care workforce, say clinical artificial intelligence poses a threat to their jobs, and patients.stat · 1mo ago
- IRBs have a problem. Can North Star’s nonprofit model save it?As institutional review boards face pressure from companies and ethicists, North Star Review Board offers a nonprofit model as more independent.stat · 1mo ago
- STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?Biotech companies don’t hide or obfuscate strong data.stat · 1mo ago
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.fiercebiotech · 1mo ago
- Avalo shares spike on skin drug data; BioNTech to cut staffAvalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.biopharma_dive · 4mo ago
Data sources
last refreshed 57m ago
Found something off?
comments(0)
5-min edit window · permanent after that